Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan

Key Takeaways

• Exclusive Japan rights for corticorelin granted to Neupharma
• Up to CHF 83.5 M upfront/milestones, 20% sales royalties
• PTBE affects 60k Japanese patients; market >$1 B globally
• Corticorelin could replace steroids, reducing severe side effects
• Pivotal trial starts 2027; US/EU Phase 3 preparation continues

Summary

Curatis Holding and Japan’s Neupharma have signed an exclusive licensing deal granting Neupharma rights to develop and market corticorelin (C‑PTBE‑01) for peritumoral brain edema (PTBE) in Japan. The agreement includes up to CHF 83.5 million in upfront and milestone payments and royalties of up to 20 % on future sales. PTBE affects roughly 60,000 patients in Japan and 500,000 worldwide, creating a market opportunity exceeding USD 1 billion annually. A pivotal Japanese trial is slated to begin in 2027 after a PMDA meeting in summer 2026, while global Phase 3 work proceeds.

Pulse Analysis

Peritumoral brain edema (PTBE) remains a critical complication of primary and metastatic brain tumours, affecting patient quality of life and limiting the efficacy of cancer therapies. Current standard‑of‑care relies on high‑dose corticosteroids, which bring a cascade of adverse effects—from glucose dysregulation to osteoporosis—and can blunt immunotherapy responses. By targeting the blood‑brain barrier, corticorelin offers a novel mechanism that may dramatically cut steroid dependence, positioning it as a potential first‑in‑class solution for an estimated 500,000 global patients.

The Curatis‑Neupharma partnership leverages each company’s strengths: Curatis brings a robust orphan‑drug portfolio and proven commercialization capabilities, while Neupharma contributes deep regulatory expertise and a track record of launching specialty medicines in Japan. Financially, the agreement secures up to CHF 83.5 million in upfront and milestone payments, plus royalty rights up to 20 %, providing Curatis with non‑dilutive funding to accelerate development. For Neupharma, exclusive rights to a therapy addressing a $1 billion‑plus market aligns with its strategy to expand into high‑impact oncology and neurology segments.

Looking ahead, the planned PMDA meeting in summer 2026 and the 2027 start of the pivotal Japanese trial set a clear regulatory pathway, while parallel Phase 3 preparations in the US and Europe keep the global rollout on schedule. Successful outcomes could reshape PTBE management, reduce reliance on harmful steroids, and generate substantial revenue streams for both partners, reinforcing the growing importance of specialty‑care collaborations in the pharmaceutical landscape.